However, skin, hepatic, and pulmonary-related irAEs are more frequent in the case of anti-PD1 antibody administration than anti-CTLA4 antibodies, it is the opposite for thyroid and lower digestive tract irAEs, such as colitis [43]. This evidence concerns the gene CTLA4 and colitis.